Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival
<p><strong>Background:</strong> Glioblastoma is the most common and aggressive primary brain tumor with extremely poor prognosis, highlighting an urgent need for developing novel treatment options. Identifying epigenetic vulnerabilities of cancer cells can provide excellen...
Egile Nagusiak: | Ozyerli-Goknar, E, Kala, EY, Aksu, AC, Bulut, I, Cingöz, A, Nizamuddin, S, Biniossek, M, Seker-Polat, F, Morova, T, Aztekin, C, Kung, SHY, Syed, H, Tuncbag, N, Gönen, M, Philpott, M, Cribbs, AP, Acilan, C, Lack, NA, Onder, TT, Timmers, HTM, Bagci-Onder, T |
---|---|
Formatua: | Journal article |
Hizkuntza: | English |
Argitaratua: |
BioMed Central
2023
|
Antzeko izenburuak
-
Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival
nork: Ezgi Ozyerli-Goknar, et al.
Argitaratua: (2023-11-01) -
EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities
nork: Yedier-Bayram, O, et al.
Argitaratua: (2022) -
The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma
nork: Ozyerli-Goknar, E, et al.
Argitaratua: (2019) -
Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer
nork: Saraç, H, et al.
Argitaratua: (2019) -
Drug Repositioning Screen on a New Primary Cell Line Identifies Potent Therapeutics for Glioblastoma
nork: Filiz Senbabaoglu, et al.
Argitaratua: (2020-12-01)